Robak P - Search Results

1

TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.

Robak T, Robak P, Smolewski P. Robak T, et al. Among authors: robak p. Curr Opin Investig Drugs. 2009 Dec;10(12):1383-90. Curr Opin Investig Drugs. 2009. PMID: 19943209 Review.

2

Richter's syndrome in the brain first manifested as an ischaemic stroke.

Robak T, Góra-Tybor J, Tybor K, Jamroziak K, Robak P, Kordek R, Rieske P, Majos A, Urbańska-Ryś H. Robak T, et al. Among authors: robak p. Leuk Lymphoma. 2004 Jun;45(6):1261-7. doi: 10.1080/10428190310001638823. Leuk Lymphoma. 2004. PMID: 15360010

3

High activity of rituximab combined with cladribine and cyclophosphamide in a patient with pulmonary lymphomatoid granulomatosis and bone marrow involvement.

Robak T, Kordek R, Urbanska-Rys H, Robak P, Bartkowiak J, Bednarek A, Chudobinski C, Chojnowski K. Robak T, et al. Among authors: robak p. Leuk Lymphoma. 2006 Aug;47(8):1667-9. doi: 10.1080/10428190600564753. Leuk Lymphoma. 2006. PMID: 16966281 No abstract available.

4

Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.

Robak P, Linke A, Cebula B, Robak T, Smolewski P. Robak P, et al. Among authors: robak t. Leuk Lymphoma. 2006 Dec;47(12):2625-34. doi: 10.1080/10428190600948147. Leuk Lymphoma. 2006. PMID: 17169808

5

Current treatment options in prolymphocytic leukemia.

Robak T, Robak P. Robak T, et al. Among authors: robak p. Med Sci Monit. 2007 Apr;13(4):RA69-80. Med Sci Monit. 2007. PMID: 17392661 Review.

6

The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies.

Robak P, Smolewski P, Robak T. Robak P, et al. Among authors: robak t. Leuk Lymphoma. 2008 Aug;49(8):1452-62. doi: 10.1080/10428190802108854. Leuk Lymphoma. 2008. PMID: 18608871 Review.

7

Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.

Robak T, Korycka A, Lech-Maranda E, Robak P. Robak T, et al. Among authors: robak p. Molecules. 2009 Mar 23;14(3):1183-226. doi: 10.3390/molecules14031183. Molecules. 2009. PMID: 19325518 Free PMC article. Review.

8

Current and emerging treatments for chronic lymphocytic leukaemia.

Robak T, Jamroziak K, Robak P. Robak T, et al. Among authors: robak p. Drugs. 2009;69(17):2415-49. doi: 10.2165/11319270-000000000-00000. Drugs. 2009. PMID: 19911856

9

Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.

Robak T, Lech-Maranda E, Robak P. Robak T, et al. Among authors: robak p. Expert Rev Anticancer Ther. 2010 Oct;10(10):1529-43. doi: 10.1586/era.10.132. Expert Rev Anticancer Ther. 2010. PMID: 20942624 Review.

10

Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.

Żołnierczyk JD, Komina O, Błoński JZ, Borowiak A, Cebula-Obrzut B, Smolewski P, Robak P, Kiliańska ZM, Węsierska-Gądek J. Żołnierczyk JD, et al. Among authors: robak p. Med Oncol. 2012 Sep;29(3):2111-26. doi: 10.1007/s12032-011-0105-8. Epub 2011 Nov 16. Med Oncol. 2012. PMID: 22086735

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

79 results

Search Page